Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study

Jiao Hu; Luzhe Yan; Jinhui Liu; Minfeng Chen; Peihua Liu; Dingshan Deng; Chaobin Zhang; Yunbo He; Benyi Fan; Huihuang Li; Guanghui Gong; Jiatong Xiao; Ruizhe Wang; Xiao Guan; Shiyu Tong; Yangle Li; Nannan Li; Zhiwang Tang; Teng Zhang; Hao Li; Bin Huang; Ning Gao; Wei He; Zhiyong Cai; Yifan Liu; Zefu Liu; Yu Gan; Yu Cui; Yuanqing Dai; Yi Cai; Zhenyu Nie; Zhenyu Ou; Jinbo Chen; Xiongbing Zu

doi:10.1002/imt2.70033

iMeta ›› 2025, Vol. 4 ›› Issue (3) :e70033 DOI: 10.1002/imt2.70033

CORRESPONDENCE

Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study

Jiao Hu ¹^,²^,³
, Luzhe Yan ¹^,²^,³
, Jinhui Liu ¹^,²^,³
, Minfeng Chen ¹^,²^,³
, Peihua Liu ¹^,²^,³
, Dingshan Deng ¹^,²^,³
, Chaobin Zhang ¹^,²^,³
, Yunbo He ¹^,²^,³
, Benyi Fan ¹^,²^,³
, Huihuang Li ¹^,²^,³
, Guanghui Gong ⁴
, Jiatong Xiao ¹^,²^,³
, Ruizhe Wang ¹^,²^,³
, Xiao Guan ¹^,²^,³
, Shiyu Tong ¹^,²^,³
, Yangle Li ¹^,²^,³
, Nannan Li ⁵
, Zhiwang Tang ⁵
, Teng Zhang ⁶
, Hao Li ⁶
, Bin Huang ⁷
, Ning Gao ⁷
, Wei He ¹^,²^,³
, Zhiyong Cai ¹^,²^,³
, Yifan Liu ¹^,²^,³
, Zefu Liu ¹^,²^,³
, Yu Gan ¹^,²^,³
, Yu Cui ¹^,²^,³
, Yuanqing Dai ¹^,²^,³
, Yi Cai ¹^,²^,³
, Zhenyu Nie ¹^,²^,³
, Zhenyu Ou ¹^,²^,³
, Jinbo Chen ¹^,²^,³
, Xiongbing Zu ¹^,²^,³^,⁸

Author information +

¹. Department of Urology, Xiangya Hospital, Central South University, Changsha, China

². National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China

³. Furong Laboratory, Changsha, China

⁴. Department of Pathology, Xiangya Hospital, Central South University, Changsha, China

⁵. Department of Urology, The First Hospital of Changsha, Changsha, China

⁶. Department of Urology, First People's Hospital of Guiyang, Guiyang, China

⁷. Department of Urology, Xiangya Boai Rehabilitation Hospital, Changsha, China

⁸. Department of Urology, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China

ouzhenyu1@163.com

chenjinbo@csu.edu.cn

zuxbxy@csu.edu.cn

Show less

History +

PDF

Cite this article

Download citation ▾

Jiao Hu, Luzhe Yan, Jinhui Liu, Minfeng Chen, Peihua Liu, Dingshan Deng, Chaobin Zhang, Yunbo He, Benyi Fan, Huihuang Li, Guanghui Gong, Jiatong Xiao, Ruizhe Wang, Xiao Guan, Shiyu Tong, Yangle Li, Nannan Li, Zhiwang Tang, Teng Zhang, Hao Li, Bin Huang, Ning Gao, Wei He, Zhiyong Cai, Yifan Liu, Zefu Liu, Yu Gan, Yu Cui, Yuanqing Dai, Yi Cai, Zhenyu Nie, Zhenyu Ou, Jinbo Chen, Xiongbing Zu. Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48-ADC) combined immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study. iMeta, 2025, 4(3): e70033 DOI:10.1002/imt2.70033

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

Sung, Hyuna, Jacques Ferlay, Rebecca L. Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, and Freddie Bray. 2021. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.” CA: A Cancer Journal for Clinicians 71: 209-249. https://doi.org/10.3322/caac.21660

[2]	Patel Vaibhav, G., K. Oh William, and D. Galsky Matthew. 2020. “Treatment of Muscle-Invasive and Advanced Bladder Cancer in 2020.” CA: A Cancer Journal for Clinicians 70: 404-423. https://doi.org/10.3322/caac.21631

[3]	Albarakati, Nada, Alaa Al-Shareeda, Majed Ramadan, Batla Al-Sowayan, Ola Negm, and Taoufik Nedjadi. 2022. “Interaction Between HER2 and ATM Predicts Poor Survival in Bladder Cancer Patients.” Journal of Cellular and Molecular Medicine 26: 4959-4973. https://doi.org/10.1111/jcmm.17512

[4]

Compérat, Eva, Mahul B. Amin, Richard Cathomas, Ananya Choudhury, Maria De Santis, Ashish Kamat, Arnulf Stenzl, Harriet C. Thoeny, and Johannes Alfred Witjes. 2022. “Current Best Practice for Bladder Cancer: A Narrative Review of Diagnostics and Treatments.” The Lancet 400: 1712-1721. https://doi.org/10.1016/S0140-6736(22)01188-6

[5]

Szabados, Bernadett, Mark Kockx, Zoe June Assaf, Pieter-Jan Van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, et al. 2022. “Final Results of Neoadjuvant Atezolizumab in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Cancer of the Bladder.” European Urology 82: 212-222. https://doi.org/10.1016/j.eururo.2022.04.013

[6]

Necchi, Andrea, Andrea Anichini, Daniele Raggi, Alberto Briganti, Simona Massa, Roberta Lucianò, Maurizio Colecchia, et al. 2018. “Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.” Journal of Clinical Oncology 36: 3353-3360. https://doi.org/10.1200/JCO.18.01148

[7]

Hu, Jiao, Jinbo Chen, Zhenyu Ou, Haige Chen, Zheng Liu, Minfeng Chen, Ruiyun Zhang, et al. 2022. “Neoadjuvant Immunotherapy, Chemotherapy, and Combination Therapy in Muscle-Invasive Bladder Cancer: A Multi-Center Real-World Retrospective Study.” Cell Reports Medicine 3: 100785. https://doi.org/10.1016/j.xcrm.2022.100785

[8]	Yan, Min, Maria Schwaederle, David Arguello, Sherri Z. Millis, Zoran Gatalica, and Razelle Kurzrock. 2015. “HER2 Expression Status in Diverse Cancers: Review of Results From 37,992 Patients.” Cancer and Metastasis Reviews 34: 157-164. https://doi.org/10.1007/s10555-015-9552-6

[9]

Koshkin, Vadim S., Christine Boyiddle, Naomi Schwartz, Judy Yu, Kristina S. Yu, Ashley Kang, Lisa Bloudek, et al. 2023. “Systematic Literature Review and Testing of HER2 Status in Urothelial Carcinoma (UC).” Journal of Clinical Oncology 41(6_suppl): 556. https://doi.org/10.1200/JCO.2023.41.6_suppl.556

[10]	Deeks, Emma D. 2021. “Disitamab Vedotin: First Approval.” Drugs 81: 1929-1935. https://doi.org/10.1007/s40265-021-01614-x

[11]	Fu, Zhiwen, Shijun Li, Sifei Han, Chen Shi, and Yu Zhang. 2022. “Antibody Drug Conjugate: The ‘Biological Missile’ for Targeted Cancer Therapy.” Signal Transduction and Targeted Therapy 7: 93. https://doi.org/10.1038/s41392-022-00947-7

[12]	Giugliano, Federica, Chiara Corti, Paolo Tarantino, Flavia Michelini, and Giuseppe Curigliano. 2022. “Bystander Effect of Antibody-Drug Conjugates: Fact or Fiction?” Current Oncology Reports 24: 809-817. https://doi.org/10.1007/s11912-022-01266-4

[13]

Sheng, Xinan, Lin Wang, Zhisong He, Yanxia Shi, Hong Luo, Weiqing Han, Xin Yao, et al. 2024. “Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.” Journal of Clinical Oncology 42: 1391-1402. https://doi.org/10.1200/JCO.22.02912

[14]

Xu, Huayan, Xinan Sheng, Li Zhou, Xieqiao Yan, Siming Li, Zhihong Chi, Chuanliang Cui, et al. 2022. “A Phase II Study of RC48-ADC in HER2-Negative Patients With Locally Advanced or Metastatic Urothelial Carcinoma.” Journal of Clinical Oncology 40(16_suppl): 4519. https://doi.org/10.1200/JCO.2022.40.16_suppl.4519

[15]

Zhou, L., K. W. Yang, S. Zhang, X. Q. Yan, S. M. Li, H. Y. Xu, J. Li, et al. 2025. “Disitamab Vedotin Plus Toripalimab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (RC48-C014): A Phase Ib/II Dose-Escalation and Dose-Expansion Study.” Annals of Oncology 36: 331-339. https://doi.org/10.1016/j.annonc.2024.12.002

[16]

Sheng, Xinan, Cuijian Zhang, Yongpeng Ji, Li Zhou, Benkui Zou, Hang Huang, Yonghua Wang, et al. 2025. “Neoadjuvant Treatment With Disitamab Vedotin Plus Perioperative Toripalimab in Patients With Muscle-Invasive Bladder Cancer (MIBC) With HER2 Expression: Updated Efficacy and Safety Results From the Phase II RC48-C017 Trial.” Journal of Clinical Oncology 43(5_suppl): 665. https://doi.org/10.1200/JCO.2025.43.5_suppl.665

[17]

Ravi, Praful, Dory Freeman, Jonathan Thomas, Arvind Ravi, Charlene Mantia, Bradley A. McGregor, Jacob E. Berchuck, et al. 2024. “Comprehensive Multiplexed Autoantibody Profiling of Patients With Advanced Urothelial Cancer.” Journal for ImmunoTherapy of Cancer 12: e008215. https://doi.org/10.1136/jitc-2023-008215

[18]	Guan, Yufeng, Xianjun Zhu, Junjie Liang, Min Wei, Shan Huang, and Xiaofen Pan. 2021. “Upregulation of HSPA1A/HSPA1B/HSPA7 and Downregulation of HSPA9 Were Related to Poor Survival in Colon Cancer.” Frontiers in Oncology 11: 749673. https://doi.org/10.3389/fonc.2021.749673

[19]	Shevtsov, Maxim, Gabriele Multhoff, Elena Mikhaylova, Atsushi Shibata, Irina Guzhova, and Boris Margulis. 2019. “Combination of Anti-Cancer Drugs With Molecular Chaperone Inhibitors.” International Journal of Molecular Sciences 20: 5284. https://doi.org/10.3390/ijms20215284

[20]

Wang, D., M. Ni, Z. Wu, M. Cao, and X. An. 2024. “287P RC48-ADC Alone or in Combination With Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma With HER2 Low/Null Expression: A Multicenter, Real-World, Retrospective Study.” Annals of Oncology 35(4_suppl): S1515. https://doi.org/10.1016/j.annonc.2024.10.307